Literature DB >> 16710669

First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?

Ricardo R Gonzalez1, Steven A Kaplan.   

Abstract

When the range of treatment options for benign prostatic hyperplasia (BPH) is as broad as the BPH spectrum of symptoms, how should urologists and their patients choose the best initial treatment? Treatment goals should include reducing both lower urinary tract symptoms and relieving associated morbidities, such as urinary retention, persistent gross hematuria, recurrent infections, bladder stones, or renal insufficiency-which are all indications for surgery. However, if one views BPH as a chronic and progressive disease, should a primary goal of BPH management be the prevention of the BPH-associated morbidities? The goal of this paper is to provide a literature update regarding various treatment options in the setting of initial treatment for symptomatic BPH. Novel approaches to BPH management are discussed. In all cases, the risks and benefits of each treatment need to be considered and discussed with the patient; the decision is ultimately up to the patient and his urologist.

Entities:  

Mesh:

Year:  2006        PMID: 16710669     DOI: 10.1007/s00345-006-0092-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  34 in total

Review 1.  The link between LUTS and ED: clinical and basic science evidence.

Authors:  Jonathan D Schiff; John P Mulhall
Journal:  J Androl       Date:  2004 Jul-Aug

2.  The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients.

Authors:  Gyan Pareek; Maria Shevchuk; Noel A Armenakas; Ljiljana Vasovic; David A Hochberg; Jay B Basillote; John A Fracchia
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

Authors:  P C Walsh; J D Madden; M J Harrod; J L Goldstein; P C MacDonald; J D Wilson
Journal:  N Engl J Med       Date:  1974-10-31       Impact factor: 91.245

4.  Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Steven A Kaplan; Konstantin Walmsley; Alexis E Te
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

5.  Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings.

Authors:  M J Hyman; A Groutz; J G Blaivas
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

6.  High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates.

Authors:  Jaspreet S Sandhu; Casey Ng; Brian A Vanderbrink; Celeste Egan; Steven A Kaplan; Alexis E Te
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

7.  Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.

Authors:  Steven A Kaplan; John D McConnell; Claus G Roehrborn; Alan G Meehan; Michael W Lee; William R Noble; John W Kusek; Leroy M Nyberg
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

8.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

Review 9.  Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy.

Authors:  Thayne R Larson
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

10.  The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms.

Authors:  T J Peters; J L Donovan; H E Kay; P Abrams; J J de la Rosette; D Porru; J W Thüroff
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

View more
  4 in total

1.  Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.

Authors:  Yasuhito Funahashi; Ryohei Hattori; Yoshihisa Matsukawa; Tomonori Komatsu; Naoto Sassa; Momokazu Gotoh
Journal:  World J Urol       Date:  2010-03-23       Impact factor: 4.226

2.  National-wide data on the treatment of BPH in Korea.

Authors:  J Y Kang; G E Min; H Son; H T Kim; H-L Lee
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-04-19       Impact factor: 5.554

3.  Factors influencing nonabsolute indications for surgery in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: analysis using causal bayesian networks.

Authors:  Myong Kim; Luis Ramirez; Changwon Yoo; Minsoo Choo; Jae-Seung Paick; Seung-June Oh
Journal:  Int Neurourol J       Date:  2014-12-29       Impact factor: 2.835

4.  Various treatment options for benign prostatic hyperplasia: A current update.

Authors:  Alankar Shrivastava; Vipin B Gupta
Journal:  J Midlife Health       Date:  2012-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.